|Day Low/High||5.46 / 5.98|
|52 Wk Low/High||4.46 / 14.93|
Investors in ZIOPHARM Oncology Inc saw new options begin trading today, for the April 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Ziopharm Oncology (ZIOP) reported stronger-than-expected results for the 2016 second quarter following Tuesday's closing bell.
Company to Host Conference Call at 4:30 PM ET Today
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a weak on high relative volume candidate
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "dead cat bounce" (down big yesterday but up big today) candidate
Levi & Korsinsky announces it has commenced an investigation of ZIOPHARM Oncology, Inc.
Goldberg Law PC ( http://www.Goldberglawpc.
The law firm of Federman & Sherwood has initiated an investigation into ZIOPHARM Oncology, Inc.
Ziopharm (ZIOP) stock is plunging in pre-market trading Friday after a brain cancer patient died soon after being injected with a gene therapy from the biopharmaceutical company.
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a pre-market mover with heavy volume candidate
The circumstances surrounding the Ziopharm patient deaths come amid heightened scrutiny of experimental anti-cancer therapies.
The lead CAR-T program of Juno Therapeutics has been placed on a clinical hold by U.S. regulators following the deaths of two patients in a pivotal clinical trial.
Trade-Ideas LLC identified ZIOPHARM Oncology (ZIOP) as a "perilous reversal" (up big yesterday but down big today) candidate
The amended agreement with Intrexon bolsters the bear argument against Ziopharm that its entire cancer drug pipeline is mediocre and overvalued.
Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new August 19th contracts and identified one put and one call contract of particular interest.
Investors considering a purchase of ZIOPHARM Oncology Inc shares, but cautious about paying the going market price of $6.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 75 cents.